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Organometallic Nucleoside Analogues: Effect of Hydroxylalkyl 
Linker Length on Cancer Cell Line Toxicity 
Jonathan L. Kedge,[a] Huy V. Nguyen,[a] Zahra Khan,[b] Louise Male,[a] Media K. Ismail, Holly V. Roberts, 
Nikolas J. Hodges,[b] Sarah L. Horswell,[a] Youcef Mehellou,[c] and James H. R. Tucker*[a] 
Dedication ((optional)) 
Abstract: A new series of chiral ferrocene derivatives containing 
both a hydroxyalkyl group and a thyminyl group on one 
cyclopentadienyl ring have been synthesised in order to probe 
structure activity relationships in cancer cell-line cytotoxicities. 
Stereoisomers of enantiomeric pairs of these so-called 
ferronucleosides have been studied and characterised by a 
combination of chiral analytical HPLC and single crystal X-Ray 
diffraction. Biological activity studies reveal that changing the 
length of the hydroxyalkyl group had marked effects on IC50 
values, with compounds having shorter arms that more closely 
resemble endogenous nucleosides exhibiting lower cytotoxicities. 
Lipophilicities and electrochemical properties of this compound 
series have been studied in order to rationalise these trends and 
indicate future directions of study. 
Introduction 
Nucleoside analogues are a class of compound which interfere 
with the processes of nucleic acid synthesis through the 
mimicking of endogenous substrates. The effectiveness of this 
class of molecules in treating cancer and various viral infections 
was established a few decades ago.[1],[2] The sugar unit in these 
drug molecules is frequently modified (e.g. in AZT or 
gemcitabine) or completely replaced (e.g. in abacovir and 
acyclovir). Fundamentally therefore, for conventional nucleoside 
mimics, the sugar unit may be viewed as a modifiable or 
replaceable linker between the active hydroxyl and nucleobase 
moieties (Figure 1).[3] 
 
Due to its stability, ease of functionalisation and potential for 
novel modes of action through its redox properties, ferrocene 
has been at the centre of the now established field of 
bioorganometallic medicinal chemistry.[4] Complementing the 
mode of action of the parent compound, the anti-malarial 
ferroquine and the breast cancer drug candidate ferrocifen are 
the most well-known examples in which beneficial secondary 
mechanisms of action are conferred upon incorporation of the 
ferrocene moiety.[5] For various ferrocene derivatives, studies 
indicate that cancer cell cytotoxicity derives from oxidation to the 
ferrocenium ion, facilitating the generation of reactive-oxygen-
species (ROS) which, in turn, inflict damage upon the genetic 
material, thereby inducing apoptosis.[5c],[6] 
 
Aiming to exploit such apposite biological properties and the 
potential for novel modes of action, we recently reported the 
promising anti-cancer activity of organometallic analogues of 
nucleosides in which the five-membered sugar ring is entirely 
replaced by a cyclopentadienyl unit in ferrocene.[7] Micro- and 
sub-micromolar activities against various cancer cell lines were 
observed for the thymine derivative 1-(S,Rp) (Figure 1) and its 
adenine counterpart containing both a hydroxyalkyl linker and a 
nucleobase. In order to establish the mode of action of these so-
called ferronucleosides, we have begun to explore the effect of 
structure and stereochemistry on cell cytotoxicity. As a starting 
point, we decided to synthesise enantiomers of two new 
thymine-containing compounds in which the hydroxyalkyl linker 
length is reduced from three to two and one carbon atoms 
respectively. The results demonstrate how small structural 
changes to these ferronucleosides can have a marked effect on 
biological activity. 
Figure 1. The DNA nucleoside thymidine, a nucleoside analogue and 
structures of the ferronucleoside target compounds in this study. 
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Results and Discussion 
The rationale for varying the linker length between the Cp ring 
and the hydroxyl group in these ferronucleoside compounds was 
as follows.  Firstly it was considered important to assess the 
effect on cell toxicity of lipophilicity. Secondly previous cancer 
cell line studies on mono-functionalised ferrocene derivatives 
had indicated that the length of an alkyl chain connected to the 
Cp ring had a marked affect on toxicity,[8] with a possible link to 
the redox potential of the ferrocene unit. Thirdly, in the spirit of 
making structural analogues of natural compounds, it was 
considered that a shorter linker length to the alcohol group 
would give compounds more closely resembling those of 
endogenous nucleosides. At the same time, it was also 
considered opportune to examine the effect of stereochemistry 
on cancer cell toxicities by synthesizing the enantiomers of 
these two new compounds. 
 
Conveniently, it was found that the two target compounds 2-(Sp) 
and 3-(Rp) could be made from one common synthon 8-(Rp), as 
was the case for their opposite enantiomers. The synthesis of 8-
(Rp) is outlined in Scheme 1. The chirally pure (S,Rp)-2-α-O-
acetoxyethyl-1-iodo-ferrocene 4-(Rp) was made accordingly to 
our previously published method[7a] and then heated in the 
presence of LiBr to give the corresponding 1-iodo-2-
vinylferrocene 5-(Rp). A hydroboration-oxidation reaction gave 
alcohol 6-(Rp) which, after benzyl protection, was treated with n-
BuLi to affect a halogen-metal exchange before quenching with 
DMF, to give the desired aldehyde 8-(Rp). 
 
Scheme 1. Synthesis of synthon 8-(Rp). 
Compound 2-(Sp) was synthesised (Scheme 2) from 8-(Rp) by 
converting the aldehyde to a vinyl group using the Wittig reaction, 
before hydroboration-oxidation placed a hydroxyl group at the β-
position. This compound was then reacted with N3-benzoyl 
thymine using the Mitsunobu reaction before removal of the 
benzyl group by hydrogenolysis and deprotection of the 
nucleobase gave the desired target compound. 
 
 
 
 
Scheme 2. Synthesis of 2-(Sp) from chiral synthon 8-(Rp). 
 
Scheme 3. Synthesis of 3-(Rp) from chiral synthon 8-(Rp). 
The route towards the methyl linker target 3-(Rp) from the same 
synthon 8-(Rp) proceeded by protecting the aldehyde as a cyclic 
acetal using 2,2-dimethylpropane-1,3-diol (Scheme 3). Benzyl 
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deprotection was again affected by hydrogenolysis, and the 
corresponding free alcohol employed in a Mitsunobu reaction 
with N3-benzoyl thymine. The acetal group was removed using 
PTSA in wet THF and the regenerated aldehyde reduced to the 
corresponding alcohol using NaBH4. Finally, the nucleobase was 
deprotected using ammonia in methanol to give the target 
compound. 
 
Compounds 2-(Rp) and 3-(Sp) were synthesised in an identical 
fashion starting from the opposite enantiomer 8-(Sp). The 
enantiopurities of these four planar chiral targets were assessed 
by analytical chiral HPLC, giving values as follows: 2-(Rp), 97%; 
2-(Sp); 97%; 3-(Rp), 95%; 3-(Sp), 92%. Fortunately, crystals of all 
four compounds, grown by the slow evaporation of concentrated 
solutions in ethyl acetate and chloroform for enantiomers of 2 
and 3 respectively, were found to be suitable for X-Ray 
diffraction. The structures of the Rp enantiomers of 2 and 3 are 
depicted in Figures 2 and 3 respectively, with those for the Sp 
enantiomers presented in the supplementary information. 
 
 
 
 
 
Figure 2. Crystal structure of 2-(Rp) with ellipsoids drawn at the 50% 
probability level. The cyclopentadienyl ring C(15)-C(19) / C(15’)-C(19’) and the 
group C(20), C(21), O(21) / C(20’), C(21’), O(21’) are both disordered over two 
positions, for clarity only the major positions are shown. 
 
Figure 3. Crystal structure of 3-(Rp) with ellipsoids drawn at the 50% 
probability level. The structure contains two crystallographically-independent 
molecules of which only one is shown. 
The Rp isomers of compounds 1, 2 and 3 were characterised 
with cyclic voltammetry (CV) in dry acetonitrile (Fig. 4) and the 
half-wave potentials, E1/2, were determined from the peak 
positions with respect to decamethylferrocene (dmfc) as the 
internal reference of (Table 1). In each case, the ratio of the 
peak heights of the oxidation and reduction waves was close to 
unity, plots of peak current vs the square root of the scan rate 
were linear and the peak separations were as measured for 
dmfc (ca. 65–70 mV), indicating reversible one-electron redox 
behaviour for all three compounds (see supplementary 
information). It is clear that as the hydroxyalkyl linker length 
increases, the E1/2 value becomes more negative, indicating the 
progressive stabilisation of the ferrocenium ion. This is 
consistent with the longer alkyl linker stabilising the ferrocenium 
cation through increased positive inductive effects, as found 
previously for related compounds.[9] 
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Figure 4. Cyclic voltammograms of 1-(S,Rp) at various scan rates wrt 
decamethylferrocene. Concentration 1.0 mM with 0.1 M TBAPF6 in dry 
acetonitrile at RT. 
Previous studies[7] indicated that 1-(S,Rp) was active in three 
different human cancer cell lines. For this study, it was decided 
to probe its activity further in a human osteosarcoma (HOS) cell 
line and compare these with its enantiomer as well as with 
compounds 2, 3 and the established anticancer drug cisplatin. 
HOS cells were exposed to various concentrations of test agent 
for four days and the cell number assessed using the crystal 
violet assay. The resulting IC50 values calculated from the 
inhibition curves are presented in Table 1. In general agreement 
with our previous studies on other cell lines,[7] 1-(S,Rp) with its 
three-carbon spacer displays low micromolar activity with an IC50 
value of 4.4 μM. However a clear trend between the length of 
the hydroxyalkyl arm and the IC50 values was observed; 
compounds 2-(Rp) and 2-(Sp) with one fewer carbon were found 
to be approximately one order of magnitude less active than 1-
(S,Rp), with IC50 values of 58.4 and 57.8 μM respectively. 
Furthermore, 3-(Rp) and 3-(Sp) with just a methylene spacer, 
display lower cytotoxicities still with IC50 values of 73.1 and 86.0 
μM respectively. Differences in biological activity between the 
European Journal of Inorganic Chemistry 10.1002/ejic.201600853
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enantiomers for compounds 2 and 3 do not appear to be 
significant.  
Figure 5. Inhibition of HOS cells after four days incubation with each 
compound. The results represent the mean of at least three independent 
experiments ± SEM (n=3).    
 
Table 1. IC50, E1/2 and CLogP values for various stereoisomers of 
ferronucleosides 1, 2 and 3. 
Compound IC50 (μM)
[a]
 E1/2 (mV)
[b]
 CLogP
[c]
 
1-(S,Rp) 4.4 424 + 0.96 
2-(Rp) 58.4 467 + 0.03 
2-(Sp) 57.8 nd + 0.03 
3-(Rp) 73.1 518 – 0.05 
3-(Sp) 86.0 nd – 0.05 
Cisplatin 0.31 – nd 
[a] 50% inhibitory concentration, or compound concentration required to 
inhibit tumor cell proliferation by 50%, after 4 days incubation. All 
compounds [b] versus decamethylferrocene, measured at 1 mM 
concentration in 0.1 M TBAPF6 in dry acetonitrile. Confidence limit ± 5mV [c] 
Calculated using ChemBioDraw Ultra 13.0.
[9a] 
nd = not determined 
(enantiomers would have identical data). 
 
As previously reported for a series of simple ferrocenyl 
compounds,[8] cell cytotoxicity is inversely related to the E1/2 
value, suggesting that biological activity could be linked to the 
thermodynamic favourability of oxidation to the ferrocenium ion 
(E1/2: 1 < 2 < 3). However another important consideration is 
lipophilicity, which would also be expected to change as a 
function of the alkyl linker length. An increase in drug activity 
with higher lipophilicity can be explained by better diffusivity 
across cellular and nuclear membranes, thus producing much 
higher concentrations at the site of action. Drug lipophilicities are 
normally quantified through octanol–water partition coefficients 
(LogP values). Predicted coefficients (as CLogP) values, 
calculated using a method previously applied to ferrocene 
compounds,[9a] are also displayed in Table 1. As expected, the 
trend in these values (CLogP: 1 > 2 > 3) also correlates with 
hydroxyalkyl arm linker length. Interestingly, lipophilicity has 
been previously shown to be linearly correlated with oxidation 
potentials for a series of structurally related ferrocene 
derivatives.[9a] 
Conclusions 
Enantiomers of two new structural variations within a series of 
ferronucleosides, in which the hydroxyalkyl linker length has 
been shortened to two and one carbon atoms respectively, have 
been successfully synthesised and characterised. The biological 
data for this novel ferrocene series demonstrate a marked 
structure activity relationship, with their cytotoxicities becoming 
progressively lower as their structure tends towards that of an 
endogenous nucleoside (i.e. thymidine). A consideration of their 
respective E1/2 and CLogP values therefore indicates that the 
thermodynamic ease of oxidation to the ferrocenium ion and 
lipophilicity may in fact be more central to their biological activity 
than their structural conformity to the traditional nucleoside 
analogue pharmacophore. Further studies are now underway to 
establish whether the mechanism of action of 1-(S,Rp) and 
related compounds resembles that of a typical nucleoside 
analogue, or a new pathway in which the structure and 
properties of the ferrocene unit play a prominent and distinct role. 
Experimental Section 
Synthesis 
 
(Rp)-1-iodo-2-vinyl-ferrocene (5-(Rp)) 
(S,Rp)-2-α-O-acetoxyethyl-1-iodo-ferrocene (4-(S,Rp)) (4.30 g, 10.81 
mmol, 1.0 eq.) was dissolved in dry DMF (20 ml), LiBr (14.0 g, 162 mmol, 
15.0 eq.) was added and the resulting mixture heated at 85 °C for 1 hr 
with stirring. The reaction was quenched by addition of sat. Na2S2O3 
solution, extracted with DCM, washed with water (2 x 100 ml), dried over 
MgSO4 and the solvent removed in vacuo. The crude product was 
purified by flash column chromatography on neutralised (Et3N) silica gel 
using an eluent of hexane. The solvent was removed in vacuo to give the 
title compound as a dark orange oil (3.40 g, 10.09 mmol, 93 %). 1H NMR 
(300 MHz, CDCl3) δ 6.58 (dd, J = 17.5, 10.9 Hz, 1H (CH=CH2), 5.50 (dd, 
J = 17.5, 1.4 Hz, 1H (CH2=CH)), 5.22 (dd, J = 10.9, 1.4 Hz, 1H 
(CH2=CH)), 4.55 (dd, J = 2.6, 1.4 Hz, 1H (Fc CH)), 4.53 (dd, J = 2.6, 1.4 
Hz, 1H (Fc CH)), 4.34 (dd, J = 2.6, 2.6 Hz, 1H (Fc CH)), 4.14 (s, 5H (cp 
CH)). 13C NMR (400 MHz, CDCl3) δ 134.21 (CH=CH2), 113.27 (CH2=CH), 
84.19 (Fc C–CH), 75.33 (Fc CH), 72.35 (cp CH), 69.54 (Fc CH), 63.80 
(Fc CH), 45.01 (Fc C–I). νmax/cm
-1 = 3087 (Fc CH), 1628 (C=C). HRMS 
(ESI-TOF) m/z: [M]+ Calcd for C12H11FeI 337.9255; Found 337.9258. 
Producing matching 1H and 13C NMR spectra, (Sp)-1-iodo-2-vinyl-
ferrocene (5-(Sp)) (2.32 g, 6.85 mmol 88 %) was prepared according to 
the same procedure from (R,Sp)-2-α-O-acetoxyethyl-1-iodo-ferrocene (4-
(R,Sp)) (3.09 g, 7.77 mmol). 
(Rp)-2-β-hydroxyethyl-1-iodo-ferrocene (6-(Rp)) 
(Rp)-1-iodo-2-vinyl-ferrocene (5-(Rp)) (3.40 g, 10.09 mmol, 1.0 eq) was 
dissolved in dry THF (30 ml) in a Schlenk tube under an atmosphere of 
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argon and cooled to 0 °C in an ice bath. BH3•THF (1M in THF) (8.87 ml, 
8.87 mmol, 1.5 eq.) was added dropwise and stirring continued at 0 °C 
for 1 hr then the solution was warmed to room temperature and stirring 
continued for another 1.5 hrs. EtOH (8.87 ml) was carefully added and 
stirring continued for 5 min, followed by the dropwise addition of NaOH 
(3M in H2O) (8.87 ml) and a further 10 min of stirring. H2O2 (30 % in H2O) 
(16 ml) was then added slowly and stirring continued for 30 min. The 
reaction was extracted with Et2O, washed with water (2 x 100 ml) and 
dried over MgSO4. The solvent was removed in vacuo and the crude 
product purified by flash column chromatography on silica gel using a 
gradient eluent system of 5 → 10 % EtOAc in hexane. The solvent was 
removed in vacuo to give the title compound as a yellow oil (3.34 g, 9.38 
mmol, 93 %). 1H NMR (300 MHz, CDCl3) δ 4.41 (dd, J = 2.5, 1.4 Hz, 1H 
(Fc CH)), 4.21 (dd, J = 2.5, 1.4 Hz, 1H (Fc CH)), 4.18 (dd, J = 2.5, 2.5 Hz, 
1H (Fc CH)), 4.12 (s, 5H (cp CH)), 3.85 – 3.62 (m, 2H (CH2OH)), 2.83 – 
2.55 (m, 2H (CH2CH2OH)), 1.61 (s, 2H (OH)). 
13C NMR (400 MHz, 
CDCl3) δ 86.22 (Fc C–CH2), 74.49 (Fc CH), 71.73 (cp CH), 68.59 (Fc 
CH), 67.71 (Fc CH), 63.00 (CH2OH), 45.51 (Fc C–I), 33.48 (CH2CH2OH). 
νmax/cm
-1 = 3303 (OH), 3092 (Fc CH). HRMS (ESI-TOF) m/z: [M]+ Calcd 
for C12H13FeIO 355.9360; Found 355.9361. 
Producing matching 1H and 13C NMR spectra, (Sp)-2-β-hydroxyethyl-1-
iodo-ferrocene (6-(Sp)) (1.37 g, 3.85 mmol, 89 %) was prepared 
according to the same procedure from (Sp)-1-iodo-2-vinyl-ferrocene (5-
(Sp)) (1.55 g, 4.34 mmol). 
(Rp)-2-β-benzyloxyethyl-1-iodo-ferrocene (7-(Rp)) 
(Rp)-2-β-benzyloxyethyl-1-iodo-ferrocene (6-(Rp)) (1.11 g, 3.13 mmol, 1.0 
eq.) was dissolved in dry DMF (25 ml) and stirred in a Schlenk tube 
under an atmosphere of argon. NaH (0.188 g, 7.83 mmol, 2.5 eq.) was 
added in small portions, the solution turned from orange to yellow and 
stirring was continued for 1 hr. BnBr (0.74 ml, 6.26 mmol, 2.0 eq.) was 
added and stirring continued for 16 hrs. The reaction was quenched by 
the dropwise addition of water, extracted with Et2O and dried over 
MgSO4. The solvent was removed in vacuo and the crude product was 
purified by flash column chromatography on silica gel using an eluent of 
hexane. The solvent was removed in vacuo to give the title compound as 
a yellow oil (1.40 g, 3.13 mmol, 100 %). 1H NMR (300 MHz, CDCl3) δ 
7.34 – 7.12 (m, 5H (Ph CH)), 4.43 (s, 2H (Ph C–CH2)), 4.28 (dd, J = 2.6, 
1.3 Hz, 1H (Fc CH)), 4.11 (dd, J = 2.6, 1.3 Hz, 1H (Fc CH)), 4.03 (dd, J = 
2.6, 2.6 Hz, 1H (Fc CH)), 3.99 (s, 5H (cp CH)), 3.62 – 3.36 (m, 2H 
(CH2CH2O), 2.73 – 2.53 (m, 2H (CH2CH2O)). 
13C NMR (400 MHz, CDCl3) 
δ 138.41 (Ph C–CH2), 128.39 (Ph CH), 127.65 (Ph CH), 127.57 (Ph CH), 
86.59 (Fc C–CH2), 74.03 (Fc CH), 72.93 (Ph C–CH2), 71.57 (cp CH), 
70.24 (CH2CH2O), 68.28 (Fc CH), 67.63 (Fc CH), 45.76 (Fc C–I), 30.63 
(CH2CH2O). νmax/cm
-1 = 3088 (Fc CH), 3029 (Ph CH). HRMS (ESI-TOF) 
m/z: [M]+ Calcd for C19H19FeIO 455.9830; Found 455.9827. 
Producing matching 1H and 13C NMR spectra, (Sp)-2-β-benzyloxyethyl-1-
iodo-ferrocene (7-(Sp)) (1.47 g, 3.30 mmol, 86 %) was prepared 
according to the same procedure from (Sp)-2-β-benzyloxyethyl-1-iodo-
ferrocene (6-(Sp)) (1.37 g, 3.85 mmol). 
(Rp)-2-β-benzyloxyethyl-1-formyl-ferrocene (8-(Rp)) 
(Rp)-2-β-benzyloxyethyl-1-iodo-ferrocene (7-(Rp)) (1.47 g, 3.28 mmol, 1.0 
eq.) was dissolved in dry Et2O (20 ml) with stirring and cooled to -78 °C 
in a Schlenk tube under argon. n-BuLi (2.5 M in hexane) (2.30 ml, 5.74 
mmol, 1.75 eq.) was added slowly and stirring continued at -78 °C for 0.5 
hrs before the reaction mixture was warmed to room temperature over 
0.5 hrs. After cooling again to -78 °C, DMF (0.76 ml, 9.84 mmol, 3.0 eq.) 
was added slowly and stirring continued for 0.5 hrs, the mixture was then 
allowed to warm to room temperature and stirring continued for 0.5 hrs. 
The reaction was quenched by the slow addition of water (10 ml), 
extracted with Et2O and dried over MgSO4. The solvent was removed in 
vacuo and the crude product purified by flash column chromatography on 
silica gel using a gradient eluent system of 0 → 30 % EtOAc in hexane. 
The solvent was removed in vacuo to give the title compound as a red oil 
(0.720 g, 2.07 mmol, 63 %). 1H NMR (300 MHz, CDCl3) δ 10.01 (s, 1H 
(CHO)), 7.33 – 7.18 (m, 6H (Ph CH)), 4.67 (dd, J = 2.7, 1.5 Hz, 1H (Fc 
CH)), 4.53 (dd, J = 2.6, 1.5 Hz, 1H (Fc CH)), 4.45 (s, 2H, (Ph C–CH2)), 
4.44 (dd, J = 2.7, 2.6 Hz, 1H (Fc CH)), 4.14 (s, 5H (cp CH)), 3.63 – 3.47 
(m, 2H (CH2CH2O)), 3.04 (ddd, J = 14.5, 6.5, 6.5 Hz, 1H (Fc C–CH2)), 
2.80 (ddd, J = 14.5, 6.8, 6.8 Hz, 1H (Fc C–CH2)). 
13C NMR (400 MHz, 
CDCl3) δ 193.82 (CHO), 138.39 (Ph C–CH2), 128.41 (Ph CH), 127.65 
(Ph CH), 127.60 (Ph CH), 88.37 (Fc C–CH2), 77.13 (Fc C–CHO), 74.72 
(Fc CH), 72.96 (Ph C–CH2), 71.50 (Fc CH), 70.79 (CH2CH2O), 70.21 (cp 
CH), 70.17 (Fc CH), 28.86 (CH2CH2O). νmax/cm
-1 = 3087 (Fc CH), 3029 
(Ph CH), (CH), 2723 (OC–H), 1669 (C=O). HRMS (ESI-TOF) m/z: [M + 
Na]+ Calcd for C20H20FeO2Na 371.0710; Found 371.0707. 
Producing matching 1H and 13C NMR spectra, (Sp)-2-β-benzyloxyethyl-1-
formyl-ferrocene (8-(Sp)) (1.05 g, 3.02 mmol, 91 %) was prepared 
according to the same procedure from (Sp)-2-β-benzyloxyethyl-1-iodo-
ferrocene (7-(Sp)) (1.47 g, 3.30 mmol). 
(Rp)-2-β-benzyloxyethyl-1-vinyl-ferrocene (9-(Rp)) 
Methyltriphenylphosphonium bromide (2.74 g, 7.67 mmol, 3.0 eq.), 
KOtBu (0.86 g, 7.67 mmol, 3.0 eq.) and dibenzo-18-crown-6 (0.005 g, 
0.013 mmol, 0.005 eq.) were dissolved in dry THF (20 ml) in a Schlenk 
tube under an atmosphere of argon and stirred for 30 mins at room 
temperature to produce a bright yellow solution. (Rp)-2-β-benzyloxyethyl-
1-formyl-ferrocene (8-(Rp)) (0.890 g, 2.56 mmol, 1.0 eq.) was dissolved in 
dry THF (20 ml) and added slowly, the resulting orange solution was 
stirred at room temperature for 1 hr. The reaction was quenched by the 
careful addition of water (20 ml), extracted with Et2O, dried over MgSO4 
and the solvent removed in vacuo. The crude product was purified by 
flash column chromatography on neutralised (Et3N) silica gel using an 
eluent of 10 % EtOAc in hexane. The solvent was removed in vacuo to 
give the title compound as an orange oil (0.869 g, 2.51 mmol, 98 %). 1H 
NMR (300 MHz, CDCl3) δ 7.51 – 7.22 (m, 5H (Ph CH)), 6.58 (dd, J = 
17.4, 10.9 Hz, 1H (CH=CH2)), 5.37 (dd, J = 17.4, 1.6 Hz, 1H (CH2=CH)), 
5.09 (dd, J = 10.9, 1.6 Hz, 1H (CH2=CH)), 4.53 (s, 2H (Ph C–CH2), 4.43 
(dd, J = 2.6, 1.4 Hz, 1H (Fc CH)), 4.20 (dd, J = 2.6, 1.4 Hz, 1H (Fc CH)), 
4.15 (dd, J = 2.6 Hz, 1H (Fc CH)), 4.03 (s, J = 2.7 Hz, 5H (cp CH)), 3.58 
(m, 2H (CH2CH2O)), 2.81 (m, 2H (CH2CH2O)). 
13C NMR (400 MHz, 
CDCl3) δ 138.51 (Ph C–C), 133.17 (CH=CH2), 128.48 (Ph CH), 127.76 
(Ph CH), 127.66 (Ph CH), 111.78 (CH2=CH), 84.12 (Fc C–CH2), 82.42 
(Fc C–CH), 73.10 (Ph C–CH2), 71.05 (CH2CH2O), 69.88 (cp CH), 69.78 
(Fc CH), 67.20 (Fc CH), 64.78 (Fc CH), 28.84 (CH2CH2O). νmax/cm
-1 = 
3085 (Fc CH), 3029 (Ph CH), 1626 (C=C). HRMS (ESI-TOF) m/z: [M + 
Na]+ Calcd for C21H22FeONa 369.0918; Found 369.0905. 
Producing matching 1H and 13C NMR spectra, (Sp)-2-β-benzyloxyethyl-1-
vinyl-ferrocene (9-(Sp)) (0.476 g, 1.37 mmol, 91 %) was prepared 
according to the same procedure from (Sp)-2-β-benzyloxyethyl-1-formyl-
ferrocene (8-(Sp)) (0.526 g, 1.51 mmol). 
(Sp)-1-β-benzyloxyethyl-2-β-hydroxyethyl-ferrocene (10-(Sp)) 
(Rp)-2-β-benzyloxyethyl-1-vinyl-ferrocene (9-(Rp)) (0.869 g, 2.51 mmol, 
1.0 eq) was dissolved in dry THF (15 ml) in a Schlenk tube under an 
atmosphere of argon and cooled to 0 °C in an ice bath. BH3•THF (1M in 
THF) (3.76 ml, 3.76 mmol, 1.5 eq.) was added dropwise and stirring 
continued at 0 °C for 15 mins before the solution was warmed to room 
temperature and stirring continued for another 1.5 hrs. The solution was 
cooled to 0 °C before EtOH (6.0 ml) was carefully added and stirring 
continued for 5 min, followed by the dropwise addition of NaOH (3M in 
H2O) (6.0 ml) and a further 10 min of stirring. H2O2 (30 % in H2O) (6.0 ml) 
was then added slowly and stirring continued for 30 min and the solution 
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allowed to warm to room temperature. The reaction was extracted with 
Et2O, washed with water (2 x 50 ml) and dried over MgSO4. The solvent 
was removed in vacuo and the crude product purified by flash column 
chromatography through a short column of neutralised (Et3N) silica gel 
using an eluent of 10 % EtOAc in hexane. The solvent was removed in 
vacuo to give the title compound as an orange oil (0.802 g, 2.20 mmol, 
88 %). 1H NMR (300 MHz, CDCl3) δ 7.38 – 7.24 (m, 5H (Ph CH)), 4.49 (s, 
2H (Ph C–CH2)), 4.14 – 4.07 (m, 2H (Fc CH)), 4.06 – 4.03 (m, 1H (Fc 
CH)), 4.02 (s, 5H (cp CH)) 3.76 – 3.45 (m, 4H (CH2CH2OCH2, CH2OH)), 
2.79 – 2.54 (m, 4H (CH2CH2OCH2, CH2CH2OH)), 2.18 (t, J = 5.9 Hz, 1H 
(OH)). 13C NMR (400 MHz, CDCl3) δ 138.23 (Ph C–CH2), 128.51 (Ph 
CH), 127.86 (Ph CH), 127.77 (Ph CH), 84.71 (Fc C–CH2CH2OCH2), 
84.35 (Fc C–CH2CH2OH), 73.13 (Ph C–CH2), 71.03 (CH2CH2OCH2), 
69.35 (cp CH), 68.31 (Fc CH), 68.21 (Fc CH), 66.32 (Fc CH), 63.67 
(CH2CH2OH), 31.68 (CH2CH2OH), 28.68 (CH2CH2OCH2). νmax/cm
-1 = 
3381 (OH), 3089 (Fc CH), 3030 (Ph CH). HRMS (ESI-TOF) m/z: [M]+ 
Calcd for C21H24FeO 364.1126; Found 364.1120. 
Producing matching 1H and 13C NMR spectra, (Rp)-1-β-benzyloxyethyl-2-
β-hydroxyethyl-ferrocene (10-(Rp)) (0.413 g, 1.13 mmol, 82 %) was 
prepared according to the same procedure from (Sp)-2-β-benzyloxyethyl-
1-vinyl-ferrocene (9-(Sp)) (0.476 g, 1.37 mmol). 
(Sp)-2-β-(N3-benzoylthyminyl)ethyl-1-β-benzyloxyethyl-ferrocene 
(11-(Sp)) 
Triphenylphosphine (0.262 g, 1.00 mmol, 2.0 eq.) and N3-
benzoylthymine (0.173 g, 0.75 mmol, 1.5 eq.) were dissolved in dry THF 
(5 ml) and stirred under an atmosphere of argon in a schlenk tube 
wrapped in foil. (Sp)-1-β-benzyloxyethyl-2-β-hydroxyethyl-ferrocene (10-
(Sp)) (0.182 g, 0.50 mmol, 1.0 eq.) dissolved in dry THF (5 ml) was 
added, followed by diethyl azodicarboxylate (0.20 ml, 1.00 mmol, 2.0 eq.) 
and the reaction mixture stirred at 75 °C for 1 hr. The reaction was 
quenched with brine (5 ml), extracted with Et2O and dried over MgSO4. 
The solvent was removed in vacuo and the crude product purified by 
flash column chromatography on neutralised (Et3N) silica gel using a 
gradient eluent system of 30 → 50 % EtOAc in hexane. The solvent was 
removed in vacuo to give the title compound as an orange solid (0.213 g, 
0.370 mmol, 74 %). m.p. 57 °C. 1H NMR (400 MHz, CDCl3) δ 7.92 (dd, J 
= 8.3, 1.3 Hz, 2H (Bz CH)), 7.63 (tt, J = 7.5, 1.3 Hz, 1H ((Bz CH)), 7.48 
(dd, J = 8.3, 7.5 Hz, 2H (Bz CH)), 7.36 – 7.25 (m, 5H (Bn CH)), 6.67 (d, J 
= 1.2 Hz, 1H (CH=C)), 4.49 (s, 1H (Bn CH2O)), 4.48 (s, 1H (Bn CH2O)), 
4.15 (dd, J = 2.5, 1.3 Hz, 1H (Fc CH)), 4.04 (dd, J = 2.5, 2.5 Hz, 1H (Fc 
CH)), 4.03 (s, 5H (cp CH)), 3.96 (dd, J = 2.5, 1.3 Hz, 1H (Fc CH)), 3.76 
(dd, J = 8.0, 6.6 Hz, 2H (CH2N)), 3.70 (ddd, J = 8.9, 5.6, 5.5 Hz, 1H 
(CH2CH2O)), 3.57 (ddd, J = 8.9, 7.1, 7.1 Hz, 1H (CH2CH2O)), 2.88 – 2.58 
(m, 4H (CH2CH2O, CH2CH2N)), 1.78 (d, J = 1.2 Hz, 3H (CH3)). 
13C NMR 
(400 MHz, CDCl3) δ 169.30 (Bz CO), 163.31 (C=C–CO–N), 149.70 (N–
CO–N), 140.95 (CH=C), 138.08 (Bn C–CH2), 134.97 (Bz CH), 131.72 (Bz 
C–CO), 130.45 (Bz CH), 129.16 (Bz CH), 128.47 (Bn CH), 127.95 (Bn 
CH), 127.82 (Bn CH), 109.62 (C=CH), 84.75 (Fc C–CH2CH2O), 82.58 (Fc 
C–CH2CH2N), 73.25 (Bn C–CH2), 71.40 (CH2CH2O), 69.32 (cp CH), 
68.45 (Fc CH), 68.38 (Fc CH), 66.41 (Fc CH), 49.54 (CH2N), 28.62 
(CH2CH2O), 27.67 (CH2CH2N), 12.26 (CH3). νmax/cm
-1 = 3075 (Fc CH), 
1744 (C=O), 1696 (C=O), 1646 (C=O), 1599 (C=C). HRMS (ESI-TOF) 
m/z: [M]+ Calcd for C33H32FeN2O4 576.1711; Found 576.1715. 
Producing matching 1H and 13C NMR spectra, (Rp)-2-β-(N3-
benzoylthyminyl)ethyl-1-β-benzyloxyethyl-ferrocene (11-(Rp)) (0.241 g, 
0.417 mmol, 37 %) was prepared according to the same procedure from 
(Rp)-1-β-benzyloxyethyl-2-β-hydroxyethyl-ferrocene (10-(Rp)) (0.413 g, 
1.13 mmol). 
(Sp)-1-β-hydroxyethyl-2-β-thyminylethyl-ferrocene (2-(Sp)) 
(Sp)-2-β-(N3-benzoylthyminyl)ethyl-1-β-benzyloxyethyl-ferrocene (11-
(Rp)) (0.213 g, 0.370 mmol) was dissolved in EtOAc (5 ml) and hydrogen 
gas bubbled through the solution with stirring using a balloon and needle. 
Pd(OH)2/C (0.30 g) was added and the resulting mixture stirred at room 
temperature with bubbling and stirring for 1 hr. The mixture was filtered 
through a short pad of celite, washed with water (2 x 5 ml) and dried over 
MgSO4. The crude product was dissolved in minimal hot EtOAc and 
allowed to cool, the title compound precipitated out as orange crystals 
which were collected by filtration and dried in vacuo (0.108 g, 0.283 
mmol, 76 %). m.p. 197 °C. [ ] 
   = -4 (±3) (c = 0.375 in methanol). 1H 
NMR (400 MHz, CDCl3) δ 10.02 (s, 1H, NH), 6.93 (d, J = 1.1 Hz, 1H 
(CH=C)), 4.13 (dd, J = 2.4, 1.3 Hz, 1H (Fc CH)), 4.04 (s, 5H, (cp CH)), 
4.03 (dd, J = 2.4, 2.4 Hz, 1H (Fc CH), 3.95 (dd, J = 2.4, 1.3 Hz, 1H (Fc 
CH)), 3.85 – 3.60 (m, 4H (CH2N, CH2OH)), 3.20 (t, J = 5.3 Hz, 1H (OH)), 
2.81 (ddd, J = 13.6, 9.1, 4.3 Hz, 1H (CH2CH2N)), 2.71 – 261 (m, 3H, 
(CH2CH2OH, CH2CH2N)), 1.90 (d, J = 1.1 Hz, 3H (CH3)). 
13C NM R (101 
MHz, CDCl3) δ 164.60 (C=C–CO–N), 151.57 (N–CO–N), 140.63 (CH=C), 
111.02 (C=CH), 84.35 (Fc C–CH2CH2OH), 82.47 (Fc C–CH2CH2N), 
69.41 (cp CH), 68.85 (Fc CH), 68.33 (Fc CH), 66.65 (Fc CH), 63.69 
(CH2OH), 50.09 (CH2N), 31.67 (CH2CH2OH), 28.20 (CH2CH2N), 12.44 
(CH3). νmax/cm
-1 = 3477 (OH), 3149 (NH), 3019 (NH), 1735.51 (C=O), 
1664.05 (C=C). HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 
C19H22FeN2O3Na 405.0878; Found 405.0874. Anal. Calcd for 
C19H22FeN2O3: C, 59.70; H, 5.80; N, 7.33. Anal. Found C, 59.67; H, 5.75; 
N, 7.52. 
(Rp)-1-β-hydroxyethyl-2-β-thyminylethyl-ferrocene (2-(Rp)) 
(Rp)-2-β-(N3-benzoylthyminyl)ethyl-1-β-benzyloxyethyl-ferrocene (11-
(Rp)) (0.240 g, 0.417 mmol) was dissolved in EtOAc (5 ml) and hydrogen 
gas bubbled through the solution using a balloon and needle with stirring. 
Pd(OH)2/C (0.30 g) was added and the resulting mixture stirred at room 
temperature with gentle bubbling and stirring for 30 mins. The mixture 
was filtered through a short pad of celite, washed with water (2 x 5 ml) 
and dried over MgSO4. The solvent was removed in vacuo and the 
alcohol purified by flash column chromatography on silica gel using an 
eluent of EtOAc. 1H and 13C NMR confirmed the successful removal of 
the benzyl group. The residue was then dissolved in NH3 (7N in MeOH) 
and stirred at room temperature for 1 hr before the solvent was removed 
in vacuo. The crude product was purified by flash column 
chromatography on silica gel using an eluent of EtOAc. Recrystalisation 
from hot EtOAc produced orange crystals which were collected by 
filtration and dried in vacuo to give the title compound (0.111 g, 0.290 
mmol, 70 %). [ ] 
   = +3 (±3) (c = 0.345 in methanol).  1H and 13C NMR 
spectra match (Sp)-1-β-hydroxyethyl-2-β-thyminylethyl-ferrocene (2-(Sp)). 
Anal. Calcd for C19H22FeN2O3: C, 59.70; H, 5.80; N, 7.33. Found: C, 
59.81; H, 5.99; N, 7.14. 
(Rp)-2-β-benzyloxyethyl-1-formyl-(3,3-dimethyl-1,5-pentanediol-
acetal)-ferrocene (12-(Rp)) 
(Rp)-2-β-benzyloxyethyl-1-formyl-ferrocene (8-(Rp)) (0.720 g, 2.07 mmol, 
1.0 eq.) was dissolved in dry DCM (20 ml) in a Schlenk tube under an 
atmosphere of argon and 4 Å molecular sieves (ca. 0.1 g) were added 
with stirring. 3,3-dimethylpentane-1,5-diol (0.431 g, 4.14 mmol, 2.0 eq.) 
was added, followed by PTSA (0.040 g, 0.21 mmol, 0.10 eq.) and the 
reaction mixture stirred under argon for 4 hrs. The reaction was 
quenched by the addition of anhydrous K2CO3 (0.25 g) and stirring 
continued for 10 minutes. The mixture was filtered through a small pad of 
celite, dried over MgSO4 and the solvent removed in vacuo. The crude 
product was purified by flash column chromatography on neutralised 
(Et3N) silica gel using an eluent of 10 % EtOAc in hexane. The solvent 
was removed in vacuo to give the title compound as an orange oil (0.772 
g, 1.78 mmol, 86 %). 1H NMR (400 MHz, CDCl3) δ 7.42 – 7.23 (m, 5H Ph 
CH)), 5.27 (s, 1H (CHOO)), 4.51 (2 x s, 2H (Ph C–CH2)), 4.31 (dd, J = 
2.5, 1.5 Hz, 1H (Fc CH)), 4.09 (s, 6H (cp CH, Fc CH)), 4.03 (dd, J = 2.5 
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Hz, 2.4 Hz 1H (Fc CH)), 3.77 – 3.44 (m, 6H (CH2CH2O, OCH2C(CH3)2)), 
2.85 (ddd, J = 14.0, 9.1, 5.7 Hz, 1H (Fc C–CH2)), 2.71 (ddd, J = 14.0, 9.4, 
6.2 Hz, 1H (Fc C–CH2)), 1.23 (s, 3H (CH3)), 0.76 (s, 3H (CH3)). 
13C NMR 
(101 MHz, CDCl3) δ 138.71 (Ph C–CH2), 128.47 (Ph CH), 127.86 (Ph 
CH), 127.63 (Ph CH), 100.68 (CHOO), 84.29 (Fc C–CHOO), 83.30 (Fc 
C–CH2), 77.88 (OCH2C(CH3)2), 77.78 (OCH2C(CH3)2), 73.06 (Ph C–CH2), 
71.17 (CH2CH2O), 69.53 (Fc CH), 69.50 (cp CH), 66.76 (Fc CH), 66.52 
(Fc CH), 30.22 (C(CH3)2), 28.88 (CH2CH2O), 23.24 (CH3), 22.05 (CH3). 
νmax/cm
-1 = 3090 (Fc CH), 3031 (Ph CH). HRMS (ESI-TOF) m/z: [M]+ 
Calcd for C25H30FeO3 434.1544; Found 434.1545. 
Producing matching 1H and 13C NMR spectra, (Sp)-2-β-benzyloxyethyl-1-
formyl-(3,3-dimethyl-1,5-pentanediol-acetal)-ferrocene (12-(Sp)) (0.586 g, 
1.35 mmol, 89 %) was prepared according to the same procedure from 
(Sp)-2-β-benzyloxyethyl-1-formyl-ferrocene (8-(Sp)) (0.526 g, 1.51 g). 
(Rp)-1-formyl-(3,3-dimethyl-1,5-pentanediol-acetal)-2-β-hydroxyethyl-
ferrocene (13-(Rp)) 
(Rp)-2-β-benzyloxyethyl-1-formyl-(3,3-dimethyl-1,5-pentanediol-acetal)-
ferrocene (12-(Rp)) (0.538 g, 1.24 mmol) was dissolved in dry DMF (10 
ml) in a round bottomed flask fitted with a rubber septum. A balloon of 
hydrogen was fitted with a long needle and the gas bubbled through the 
solution; a second needle through the septum allowed the pressure to 
equalise. Pd(OH)2/C (0.30 g) was added and the solution carefully stirred 
with continued bubbling of hydrogen gas. The reaction was carefully 
monitored by TLC until, after 20 minutes all starting material was 
consumed. The hydrogen balloon was removed and the reaction mixture 
filtered through a small pad of celite. Brine (20 ml) was added, the crude 
product extracted with Et2O and dried over MgSO4. The crude product 
was then purified by flash column chromatography on neutralised (Et3N) 
silica gel using an eluent of 30 % EtOAc in hexane. The solvent was 
removed in vacuo to give the title compound as an orange oil (0.305 g, 
0.885 mmol, 71 %). 1H NMR (400 MHz, CDCl3) δ 5.31 (s, 1H (CH)), 4.37 
(dd, J = 2.0, 2.0 Hz, 1H (Fc CH)), 4.11 (s, 5H (cp CH)), 4.10 – 4.07 (m, 
2H (Fc CH)), 3.80 – 3.69 (m, 1H (CH2OH)), 3.75 (dd, J = 11.1, 2.5 Hz, 1H 
(CH2OCH)), 3.67 (dd, J = 11.0, 2.6 Hz, 1H (CH2OCH)), 3.61 (dd, J = 11.1, 
0.9 Hz, 1H (CH2OCH)), 3.60 (dd, J = 11.0, 0.9 Hz, 1H (CH2OCH)) 3.59 – 
3.51 (m, 1H (CH2OH)), 2.76 (ddd, J = 14.5, 8.7, 4.7 Hz, 1H (CH2CH2OH)), 
2.75 (s, 1H (OH)) 2.63 (ddd, J = 14.5, 5.5, 4.2 Hz, 1H (CH2CH2OH)), 1.23 
(s, 3H (CH3), 0.77 (s, 3H (CH3)). 
13C NMR (101 MHz, CDCl3) δ 100.55 
(CH), 84.43 (Fc C–CH), 84.06 (Fc C–CH2), 77.90 (CH2OCH), 77.71 
(CH2OCH), 69.72 (Fc CH), 69.57 (cp CH), 67.08 (Fc CH), 66.91 (Fc CH), 
64.14 (CH2OH), 32.11 (CH2CH2OH), 30.20 (C(CH3)2), 23.18 (CH3), 21.97 
(CH3). νmax/cm
-1 = 3420 (OH), 3095 (Fc CH). HRMS (ESI-TOF) m/z: [M]+ 
Calcd for C18H24FeO3 344.1075; Found 344.1084. 
Producing matching 1H and 13C NMR spectra, (Sp)-1-formyl-(3,3-
dimethyl-1,5-pentanediol-acetal)-2-β-hydroxyethyl-ferrocene (13-(Sp)) 
(0.367 g, 1.066 mmol, 79 %) was prepared according to the same 
procedure from (Sp)-2-β-benzyloxyethyl-1-formyl-(3,3-dimethyl-1,5-
pentanediol-acetal)-ferrocene (12-(Sp)) (0.583 g, 1.34 mmol). 
(Rp)-2-β-(N3-benzoylthyminyl)ethyl-1-formyl-(3,3-dimethyl-1,5-
pentanediol-acetal)ferrocene (14-(Rp)) 
Triphenylphosphine (0.596 g, 2.27 mmol, 1.5 eq.) and N3-
benzoylthymine (0.454 g, 1.97 mmol, 1.3 eq.) were dissolved in dry THF 
(10 ml) and stirred under an atmosphere of argon in a schlenk tube 
wrapped in foil. (Rp)-1-formyl-(3,3-dimethyl-1,5-pentanediol-acetal)-2-β-
hydroxyethyl-ferrocene (13-(Rp)) (0.522 g, 1.52 mmol, 1.0 eq.) dissolved 
in dry THF (10 ml) was added, followed by diethyl azodicarboxylate (0.45 
ml, 2.27 mmol, 1.5 eq.) and the reaction mixture stirred at 75 °C for 2 hrs. 
The reaction was quenched with brine (10 ml), extracted with Et2O and 
dried over MgSO4. The solvent was removed in vacuo and the crude 
product purified by flash column chromatography on neutralised (Et3N) 
silica gel using a gradient eluent system of 10 → 40 % EtOAc in hexane. 
The solvent was removed in vacuo to give the title compound as an 
yellow solid (0.221 g, 0.398 mmol, 65 %). m.p. 87 °C. 1H NMR (400 MHz, 
CDCl3) δ 7.91 (dd, J = 8.1, 1.2 Hz, 2H (Ph CH)), 7.63 (tt, J = 7.4, 1.2 Hz, 
1H (Ph CH)), 7.48 (dd, J = 8.1, 7.4 Hz, 2H (Ph CH)), 6.78 (d, J = 1.0 Hz, 
1H (CH=C)), 5.30 (s, 1H (CHOO)), 4.34 (dd, J = 2.4, 1.5 Hz, 1H (Fc CH)), 
4.11 (s, 5H (cp CH)), 4.06 (dd, J = 2.4, 2.2 Hz, 1H (Fc CH)), 4.05 – 3.96 
(m, 1H (CH2N)), 3.95 (dd, J = 2.2, 1.5 Hz, 1H (Fc CH)), 3.76 – 3.67 (m, 
3H (CH2N, CH2O)), 3.61 (d, J = 10.7 Hz, 2H (CH2O), 2.94 (ddd, J = 14.0, 
6.8, 4.4 Hz, 1H (OCH2C(CH3)2)), 2.77 (ddd, J = 14.0, 8.4, 7.6 Hz, 1H 
(OCH2C(CH3)2)), 1.79 (d, J = 1.0 Hz, 3H (CH3C=CH)), 1.24 (s, 3H 
(CH3CCH3)), 0.78 (s, 3H (CH3CCH3)). 
13C NMR (101 MHz, CDCl3) δ 
169.36 (Bz CO), 163.46 (C–CO–N), 149.77 (N–CO–N), 141.51 (CH=C), 
134.94 (Ph CH), 131.83 (Ph C–CO), 130.49 (Ph CH), 129.16 (Ph CH), 
109.42 (C=CH), 100.95 (CHOO), 84.06 (Fc C–CH), 81.97 (Fc C–CH2), 
77.91 (CH2O), 77.79 (CH2O), 70.01 (Fc CH), 69.63 (cp CH), 67.83 (Fc 
CH), 66.87 (Fc CH), 50.06 (CH2N), 30.16 (C(CH3)2), 27.92 (CH2CH2N), 
23.32 (CH3CCH3), 21.97 (CH3CCH3), 12.21 (CH3C=CH). νmax/cm
-1 = 
3088 (Fc CH), 1745 (C=O), 1697 (C=O), 1647 (C=O), 1599 (C=C). 
HRMS (ESI-TOF) m/z: [M]+ Calcd for C30H32FeN2O5 556.1661; Found 
556.1669. 
Producing matching 1H and 13C NMR spectra, (Sp)-2-β-(N3-
benzoylthyminyl)ethyl-1-formyl-(3,3-dimethyl-1,5-pentanediol-
acetal)ferrocene (14-(Sp)) (0.456 g, 0.819 mmol, 77 %) was prepared 
according to the same procedure from (Sp)-1-formyl-(3,3-dimethyl-1,5-
pentanediol-acetal)-2-β-hydroxyethyl-ferrocene (13-(Sp)) (0.367 g, 1.07 
mmol). 
(Rp)-2-β-(N3-benzoylthyminyl)ethyl-1-formyl-ferrocene (15-(Rp)) 
(Rp)-2-β-(N3-benzoylthyminyl)ethyl-1-formyl-(3,3-dimethyl-1,5-
pentanediol-acetal)ferrocene (14-(Rp)) (0.329 g, 0.591 mmol, 1.0 eq.) 
was dissolved in a mixture of THF (8 ml) and water (2ml) to produce a 
yellow solution. PTSA (0.056 g, 0.296 mmol, 0.5 eq.) was added and the 
resulting mixture stirred at room temperature for 45 min to produce a red 
solution. The reaction was quenched by the slow addition of sat. NaHCO3 
solution, extracted with EtO2, dried over MgSO4 and the solvent removed 
in vacuo. The crude product was purified by flash column 
chromatography using an eluent of 50 % EtOAc in hexane and the 
solvent was removed in vacuo to give the title compound as an red solid 
(0.277 g, 0.589 mmol, 100 %). m.p. 69 °C. 1H NMR (300 MHz, CDCl3) δ 
10.01 (s, 1H (CHO)), 7.94 (dd, J = 8.4, 1.3 Hz, 2H (Ph CH)), 7.64 (tt, J = 
7.4, 1.3 Hz, 1H (Ph CH)), 7.50 (dd, J = 8.4, 1.3 Hz, 2H (Ph CH)), 7.02 (d, 
J = 1.2 Hz, 1H (CH=C)), 4.70 (dd, J = 2.7, 1.4 Hz, 1H (Fc CH)), 4.53 (dd, 
J = 2.6, 1.5 Hz, 1H (Fc CH)), 4.50 (dd, J = 2.6 Hz, 1H (Fc CH)), 4.24 (s, J 
= 4.0 Hz, 5H (cp CH)), 3.98 (ddd, J = 13.4, 8.4, 7.0 Hz, 1H (CH2N)), 3.69 
(ddd, J = 13.6, 8.7, 5.1 Hz, 1H (CH2N)), 3.21 (ddd, J = 13.5, 8.4, 5.1 Hz, 
1H (CH2)), 2.93 (ddd, J = 13.6, 8.5, 7.1 Hz, 1H (CH2)), 1.89 (d, J = 1.0 Hz, 
3H (CH3)). 
13C NMR (101 MHz, CDCl3) δ 194.49 (CHO), 169.34 (Bz CO), 
163.41 (C–CO–N), 149.89 (N–CO–N), 140.82 (CH=C), 135.04 (Ph CH), 
131.84 (Ph C–CO), 130.62 (Ph CH), 129.22 (Ph CH), 110.36 (C=CH), 
85.16 (Fc C–CH2), 75.47 (Fc CH), 73.03 (Fc CH), 72.03 (Fc CH), 70.49 
(cp CH), 50.01 (CH2N), 29.80 (Fc C–CO), 28.58 (CH2CH2N), 12.37 (CH3). 
νmax/cm
-1 = 3068 (Ph CH), 1741 (C=O), 1694 (C=O), 1641 (C=O), 1598 
(C=C). HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C25H22FeN2O4Na 
493.0827; Found 493.0825. 
Producing matching 1H and 13C NMR spectra, (Sp)-2-β-(N3-
benzoylthyminyl)ethyl-1-formyl-ferrocene (15-(Sp)) (0.333 g, 0.707 mmol, 
86 %) was prepared according to the same procedure from (Sp)-2-β-(N3-
benzoylthyminyl)ethyl-1-formyl-(3,3-dimethyl-1,5-pentanediol-
acetal)ferrocene (14-(Sp)) (0.454 g, 0.819 mmol). 
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(Rp)-2-β-(N3-benzoylthyminyl)ethyl-1-hydroxymethyl-ferrocene (16-
(Rp)) 
(Rp)-2-β-(N3-benzoylthyminyl)ethyl-1-formyl-ferrocene (15-(Rp)) (0.055 g, 
0.117 mmol, 1.0 eq.) was dissolved in MeOH (5 ml) and cooled to 0 °C 
with stirring. NaBH4 (0.008 g, 0.233 mmol, 2.0 eq.) was added to the red 
solution and stirring continued for 15 min at 0 °C. The resulting yellow 
solution was quenched with brine, extracted with DCM and dried over 
MgSO4. The crude product was purified by flash column chromatography 
using an eluent of 40 % hexane in EtOAc, the solvent was removed in 
vacuo to give the title compound as a yellow oil (0.053 g, 0.113 mmol, 
96 %). 1H NMR (400 MHz, CDCl3) δ 7.87 (dd, J = 8.2, 1.3 Hz, 2H (Ph 
CH)), 7.71 – 7.58 (m, J = 7.5, 1.3 Hz, 1H (Ph CH)), 7.48 (dd, J = 8.2, 7.5 
Hz, 2H (Ph CH)), 6.93 (d, J = 1.2 Hz, 1H (CH=C)), 4.47 (d, J = 11.9 Hz, 
1H (CH2OH)), 4.31 (d, J = 11.9 Hz, 1H (CH2OH)), 4.19 (s, 1H (Fc CH)), 
4.11 (t, J = 2.1 Hz, 1H (Fc CH)), 4.08 (s, 5H (cp CH)), 4.04 (s, 1H (Fc 
CH)), 3.91 (ddd, J = 13.7, 8.5, 7.4 Hz, 1H (CH2CH2N)), 3.76 (ddd, J = 
13.6, 7.8, 4.4 Hz, 1H (CH2CH2N)), 2.85 (ddd, J = 14.2, 7.3, 4.4 Hz, 1H 
(CH2CH2N)), 2.74 (dt, J = 14.2, 8.2 Hz, 1H (CH2CH2N)), 2.40 (s, 1H 
(OH)), 1.86 (d, J = 1.2 Hz, 3H (CH3)). 
13C NMR (101 MHz, CDCl3) δ 
169.27 (Bz CO), 163.34 (C–CO–N), 150.06 (N–CO–N), 140.69 (CH=C), 
135.09 (Ph CH), 131.67(Ph C–CO), 130.62 (Ph CH), 129.20 (Ph CH), 
110.43 (C=CH), 85.57 (Fc C–CH2CH2), 83.04 (Fc C–CH2OH), 70.04 (Fc 
CH), 69.93 (Fc CH), 69.22 (cp CH), 67.19 (Fc CH), 59.45 (CH2OH), 
49.90 (CH2N), 27.85 (CH2CH2N), 12.33 (CH3). νmax/cm
-1 = 3474 (OH), 
3072 (Ph CH), 1743 (C=O), 1693 (C=O), 1639 (C=O), 1599 (C=C). 
HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C25H24FeN2O4Na 495.0983; 
Found 495.0972. 
Producing matching 1H and 13C NMR spectra, (Sp)-2-β-(N3-
benzoylthyminyl)ethyl-1-hydroxymethyl-ferrocene (16-(Sp)) (0.329 g, 
0.697 mmol, 99 %) was prepared according to the same procedure from 
(Sp)-2-β-(N3-benzoylthyminyl)ethyl-1-formyl-ferrocene (15-(Sp)) (0.333 g, 
0.707 mmol). 
(Rp)-1-hydroxymethyl-2-β-thyminylethyl-ferrocene (3-(Rp)) 
(Rp)-2-β-(N3-benzoylthyminyl)ethyl-1-hydroxymethyl-ferrocene (16-(Rp)) 
(0.0327 g, 0.069 mmol) was dissolved in MeOH (2 ml) before excess 
MeNH2 (30 % in MeOH) (0.2 ml) was added and the resulting mixture 
was stirred at room temperature for 5 min. Brine (5 ml) was added, the 
crude product extracted with DCM, dried over MgSO4 and the solvent 
removed in vacuo. The crude product was purified by flash column 
chromatography on silica gel using an eluent of 20 % hexane in EtOAc. 
Recrystallisation by the slow evaporation of a concentrated solution in 
chloroform produced orange crystals and the solvent was removed in 
vacuo to give an orange solid. Recrystallisation from a concentrated 
solution in chloroform produced single orange crystals of the title 
compound (0.025 g, 0.067 mmol, 93 %). Decomposes above 159 °C. 
[ ] 
   = -9 (±3) (c = 0.25 in methanol). 1H NMR (300 MHz, CDCl3) δ 8.68 
(s, 1H (NH)), 6.82 (d, J = 1.2 Hz, 1H (CH=C)), 4.52 (d, J = 12.0 Hz, 1H 
(CH2OH)), 4.37 (d, J = 12.0 Hz, 1H (CH2OH)), 4.20 (dd, J = 2.5, 1.4 Hz, 
1H (Fc CH)), 4.17 – 4.10 (m, 1H (Fc CH)), 4.08 (s, 5H (cp CH)) 4.00 (dd, 
J = 2.3, 1.4 Hz, 1H (Fc CH)), 3.81 (dd, J = 8.3, 1.3 Hz, 1H (CH2N)), 3.79 
(d, J = 8.3 Hz, 1H (CH2N)), 2.89 – 2.66 (m, 2H (CH2CH2N)), 2.17 (s, 1H 
(OH)), 1.85 (d, J = 1.2 Hz, 3H (CH3)). 
13C NMR (101 MHz, CDCl3) δ 
164.12 (C–CO–N), 150.99 (N–CO–N), 140.89 (CH=C), 110.47 (C=CH), 
85.65 (Fc C–CH2CH2), 83.11 (Fc C–CH2OH), 70.01 (Fc CH), 69.73 (Fc 
CH), 69.11 (cp CH), 67.14 (Fc CH), 59.56 (CH2OH), 49.97 (CH2N), 28.05 
(CH2CH2N), 12.32 (CH3). νmax/cm
-1 = 3411 (OH), 1658 (C=O), 1627 
(C=C). HRMS (ESI-TOF) m/z: [M]+ Calcd for C18H20FeN2O3 368.0823; 
Found 368.0811. Anal. Calcd for C18H20FeN2O3: C, 58.72; H, 5.48; N, 
7.61. Found: C, 58.91; H, 5.45; N, 7.74.  
Producing matching 1H and 13C NMR spectra, (Sp)-1-hydroxymethyl-2-β-
thyminylethyl-ferrocene (3-(Sp)) (0.245 g, 0.665 mmol, 95 %) was 
prepared according to the same procedure from (Sp)-2-β-(N3-
benzoylthyminyl)ethyl-1-hydroxymethyl-ferrocene (16-(Sp)) (0.329 g, 
0.697 mmol). [ ] 
   = +3 (±3) (c = 0.28 in methanol). Anal. Calcd for 
C18H20FeN2O3: C, 58.72; H, 5.48; N, 7.61Anal. Found C, 58.80; H, 5.55; 
N, 7.47. 
Electrochemistry 
Electrochemical measurements were performed in dry and de-
oxygenated acetonitrile solutions. The base electrolyte was 0.1 M 
tetrabutylammonium hexafluorophosphate (TBAPF6, ≥ 99%, Fluka). 
Solutions of compounds 1-(Rp), 2-(Rp), and 3-(Rp) were made in this 
electrolyte at concentrations of 1.0 mM and 1 mM decamethylferrocene 
(dmfc) was added to serve as an internal reference. (The measured E1/2 
of dmfc vs 
with the literature.[10] The measurements were performed on a 
BioAnalytical Systems Inc. (West Lafayette, IN) EC epsilon potentiostat 
using a C3 cell stand and a traditional 3-electrode set-up. Measurements 
were carried out at room temperature. All electrodes were purchased 
from IJ Cambria (Llanelli, Wales). The working electrode was a glassy 
carbon electrode of 3 mm diameter, the counter electrode was a platinum 
wire and the reference electrode was a Ag|AgCl|3 M KCl electrode 
(BASi), housed in a compartment connected to the cell via a frit. 
Prior to use, all glassware was cleaned by immersing in a 1:1 mixture of 
ammonia (35%) and hydrogen peroxide (30%) for several hours and then 
rinsed with copious quantities of ultrapure water (purified with a Millipore 
tandem Elix-A10 system, resistivity > 18 MΩ cm, TOC < 5 ppb). The 
glassware was soaked overnight in ultrapure water and dried carefully 
before use. The counter electrode was prepared by flame annealing and 
the reference electrode was rinsed with acetonitrile before each use. The 
working electrode was prepared by polishing in successively finer grades 
of alumina slurry (1.0 μm, 0.3 μm, 0.05 μm), rinsed with ultrapure water 
and then acetonitrile. It was carefully dried under a stream of argon and 
placed in the electrochemical cell containing the test solution. Molecular 
sieves were used to maintain dryness of the solvent and an argon 
blanket was maintained in the cell during the measurements. 
 
Biological Studies 
Cell culture: HOS osteosarcoma cells (87070202) were obtained from the 
European General Cell culture collection and routinely cultured in T75 
cell culture flasks using DMEM supplemented with 10% v/v foetal calf 
serum, 2 mM glutamine, 100U/ml penicillin and 100μg/ml streptomycin. 
Cells were passaged twice weekly using a trypsin-EDTA solution and 
reseeded in a fresh T75 flask at an approximate dilution of 1:3.  
Crystal violet assay: Cells were seeded in a 96-well plate at a density of 
6250 cells per well in 100 μL of media and left to attach overnight. The 
next day the media was removed and replaced with fresh media 
containing the appropriate concentration of test compound prepared from 
a 10 mM stock solution of test compound dissolved in DMSO (storage of 
1-(S,Rp) in this solvent over a period of 12 months at 4 
oC gave no 
evidence of degradation, as monitored by 1-H NMR).  All compounds 
were fully soluble in PBS buffer at the concentrations used; the final 
concentration of DMSO in all wells was 1% v/v. After 4 days incubation 
the media was removed and wells washed with 100μl of phosphate 
buffered saline solution (PBS). Next, 4% paraformaldehyde (100  μL  per 
well) was added and the plates incubated at room temperature for 15 
minutes to allow fixation of the cells. The paraformaldehyde was 
removed and crystal violet (100 μl of 0.5% w/v, dissolved in 10% ethanol, 
90% distilled water) added and plates left at room temperature for 20 
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minutes to allow staining of the cells. The crystal violet solution was 
removed and wells were washed three times with 100 μl of distilled water 
and allowed to air dry for approximately 20 minutes. Once the cells were 
dry, 100 μl of 10% v/v acetic acid was added to each well and the plates 
were left at room temperature for 20 minutes to allow the stain to dissolve. 
Absorbance was read at 590 nm wavelength against a blank of acetic 
acid solution alone in a plate reader. 
X-Ray Crystallography  
Table 2. Selected crystal data for 2-(Rp), 2-(Sp), 3-(Rp) and 3-(Sp) 
 2-(Rp) 2-(Sp) 3-(Rp) 3-(Sp) 
Empirical 
Formula 
C19H22FeN2
O3 
C19H22FeN2
O3 
C18H20FeN2
O3 
C18H20FeN2
O3 
Formula 
Weight 
382.23 382.23 368.21 368.21 
Temperatu
re (K) 
100.01(10) 100.0(3) 99.98(12) 100.00(10)  
Crystal 
System 
Tetragonal 
Orthorhomb
ic 
Orthorhomb
ic 
Orthorhomb
ic 
Space 
Group 
P43212 (no. 
96) 
P212121 (no. 
19) 
P212121 (no. 
19) 
P212121 (no. 
19) 
a ; b ; c  
(Å) 
11.96948(1
0) ; 
11.96948(1
0) ; 
24.1571(3) 
11.8672(3) ;  
12.1205(3) ; 
24.1747(5) 
11.3617(3) ; 
11.8847(3) ;  
23.7138(6) 
11.3958(6) ;  
11.8730(6) ; 
23.7314(10) 
V (Å3) 3460.95(7) 3477.19(13) 3202.07(14) 3210.9(3) 
Z ; Z’ 8 ; 1 8 ; 2 8 ; 2 8 ; 2 
calc 
(g/cm3) 
1.467 1.460 1.528 1.523 
μ(MoKα) 
(mm-1) 
0.892 0.888 0.961 0.958 
 (Å) 0.71073 0.71073 0.71073 0.71073 
F(000) 1600.0 1600.0 1536.0 1536.0 
2 Range 
for Data 
Collection 
() 
4.792 – 
58.954 
4.76 – 
52.74 
6.856 – 
54.962 
4.954 – 
56.56 
Index 
Ranges 
-16 ≤ h ≤ 
15, 
-15 ≤ k ≤ 16, 
-31 ≤ l ≤ 33 
-14 ≤ h ≤ 
14, 
-15 ≤ k ≤ 
15, 
-30 ≤ l ≤ 29 
-14 ≤ h ≤ 
14, 
-14 ≤ k ≤ 
15, 
-30 ≤ l ≤ 30 
-14 ≤ h ≤ 
10, 
-14 ≤ k ≤ 
15, 
-29 ≤ l ≤ 31 
Reflection
s 
Collected 
71538 35875 34740 24084 
Independe
nt 
Reflection
s 
4700 [Rint = 
0.0401] 
7092 [Rint = 
0.0418] 
7237 [Rint = 
0.0381] 
7488 [Rint = 
0.0481] 
Goodness-
of-Fit on 
F2 
1.085 1.053 1.097 1.132 
Final R 
Indices 
[I>=2σ (I)] 
R1 = 
0.0410,  
wR2 = 
0.0948 
R1 = 
0.0571,  
wR2 = 
0.1389 
R1 = 
0.0318,  
wR2 = 
0.0743 
R1 = 
0.0495,  
wR2 = 
0.1091 
Final R 
Indices (All 
Data) 
R1 = 
0.0542,  
wR2 = 
0.1030 
R1 = 
0.0632,  
wR2 = 
0.1442 
R1 = 
0.0332,  
wR2 = 
0.0751 
R1 = 0.543,  
wR2 = 
0.1112 
Largest 
Diff. Peak ; 
Hole (e Å-
0.39; -0.40 0.73 ; -0.69 1.11 ; -0.28 1.03 ; -0.40 
3) 
Flack 
Parameter 
-0.003(5) 0.018(6) 0.003(5) 0.018(7) 
CCDC  1492565 1492566 1492567 1492568 
 
The datasets for 2-(Rp), 2-(Sp), 3-(Rp) and 3-(Sp) were measured on an 
Agilent SuperNova diffractometer using an Atlas detector. The data 
collections were driven and processed and numerical absorption 
corrections based on gaussian integration over a multifaceted crystal 
model were applied using CrysAlisPro.[11] The structures were solved 
using ShelXS [12] and refined by a full-matrix least-squares procedure on 
F2 in ShelXL.[12] Figures and reports were produced using OLEX2.[13] The 
structures of 2-(Sp), 3-(Rp) and 3-(Sp) all contain two crystallographically-
independent molecules. All non-hydrogen atoms in all four structures 
were refined with anisotropic displacement parameters. In the structures 
of 2-(Rp), 3-(Rp) and 3-(Sp) the hydrogen atoms bonded to nitrogen and 
oxygen atoms were located in the electron density and the positions 
refined, with the remaining hydrogen atoms being fixed as riding models. 
The Uiso of all hydrogen atoms were based on the Ueq of the parent 
atoms. In 2-(Sp) the hydrogen atoms bonded to N(3) and N(103) were 
located in the electron density and the positions and thermal parameters 
refined while the remaining hydrogen atoms were fixed as riding models 
with the Uiso of the hydrogen atoms being based on the Ueq of the parent 
atoms. 2-(Rp): The cyclopentadienyl ring C(15)-C(19) / C(15’)-C(19’) is 
disordered over two positions with the refined occupancy ratio being 
0.591(19):0.409(19). The group C(20), C(21), O(21) / C(20’), C(21’), 
O(21’) is disordered over two positions with the occupancy ratio fixed due 
to symmetry constraints at 0.5:0.5. 2-(Sp): The cyclopentadienyl ring 
C(15)-C(19) / C(15’)-C(19’) is disordered over two positions with the 
refined occupancy ratio being 0.58(3):0.42(3). The group C(20), C(21), 
O(21) / C(0’), C(1’), O(1’) is disordered over two positions with the refined 
occupancy ratio being 0.581(14):0.419(14). The group C(120), C(121), 
O(121) / C(20’), C(21’), O(21’) is disordered over two positions with the 
refined occupancy ratio being 0.525(11):0.475(11). 3-(Sp): The group 
C(120)-O(120)/C(20’)-O(20’) is disordered over two positions with the 
refined occupancy ratio being 0.729(11):0.271(11). 
CCDC-1492565 – CCDC-1492568 contain the supplementary 
crystallographic data for this paper. These data can be obtained free of 
charge from The Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
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